Literature DB >> 8635694

Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production .

F Annunziato1, R Manetti, I Tomasévic, M G Guidizi, R Biagiotti, V Giannò, P Germano, C Mavilia, E Maggi, S Romagnani.   

Abstract

The lymphocyte activation gene (LAG) -3 is a member of the immunoglobulin super-family that is selectively transcribed in human activated T and NK cells. In this work, the possibility that LAG-3 expression by human CD4+ T cells was preferentially related to one or another phenotype of cytokine secretion was investigated. Surface LAG-3 expression correlated with IFN-gamma, but not IL-4, production in antigen-stimulated T cells and it was up-regulated by IL-12. Most activated CD4+ T cell clones with established Th1 or Th0 profiles of cytokine secretion expressed LAG-3 on their surface, whereas the great majority of Th2 clones showed neither surface LAG-3 nor LAG-3 mRNA expression. After activation, the majority of CD4+ T cell clones also released soluble LAG-3-related peptides, and such a release correlated positively with the production of IFN-gamma and inversely with the production of IL-4. Thus, LAG-3 expression by activated CD4+ human T cells appear to be preferentially associated with the differentiation/activation pathway leading to the production of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635694     DOI: 10.1096/fasebj.10.7.8635694

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

1.  A novel surface molecule of Th2- and Tc2-type cells, CRTH2 expression on human peripheral and decidual CD4+ and CD8+ T cells during the early stage of pregnancy.

Authors:  H Tsuda; T Michimata; M Sakai; K Nagata; M Nakamura; S Saito
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Authors:  Jun Wang; Miguel F Sanmamed; Ila Datar; Tina Tianjiao Su; Lan Ji; Jingwei Sun; Ling Chen; Yusheng Chen; Gefeng Zhu; Weiwei Yin; Linghua Zheng; Ting Zhou; Ti Badri; Sheng Yao; Shu Zhu; Agedi Boto; Mario Sznol; Ignacio Melero; Dario A A Vignali; Kurt Schalper; Lieping Chen
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

3.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease.

Authors:  P Parronchi; P Romagnani; F Annunziato; S Sampognaro; A Becchio; L Giannarini; E Maggi; C Pupilli; F Tonelli; S Romagnani
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

4.  Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

Authors:  B Huard; R Mastrangeli; P Prigent; D Bruniquel; S Donini; N El-Tayar; B Maigret; M Dréano; F Triebel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 5.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 6.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 7.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  Decreased LAG3 expression on T effector cells and regulatory T cells in SAA.

Authors:  Yingying Sun; Chunyan Liu; Ting Jiao; Ning Xie; Huaquan Wang; Weiwei Qi; Zonghong Shao
Journal:  Int J Hematol       Date:  2020-08-12       Impact factor: 2.490

9.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 10.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.